Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTIO-UC: DDR gene alterations and response to platinum-based chemotherapy in advanced urothelial cancer
2024-516450-21-00Phase 4Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemcitabine, cisplatin, carboplatin and avelumab in transitional cell carcinoma (TCC), sponsored by Policlinico Gemelli. Primary endpoint: Objective response rate by DDR alteration status. Planned start Dec 2024; status: authorised.
02
Drugs
gemcitabinecisplatincarboplatinavelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-516450-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516450-21-00.